Contract development and manufacturing organisation (CDMO) apceth Biopharma has promoted Dusan Kosijer to chief financial officer (CFO), a role that will see him further progress the firm’s business and executive strategy.
He joined Munich-based cell therapy-focused company in 2016 and was initially responsible for the company’s finance strategy and operations and the leadership of the accountant and purchasing team.
He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene therapy.
“We will continue to be relentless in our efforts to be the best and most reliable CDMO partner for the growing number of our renowned international clients.
“In parallel, apceth’s pipeline has recently entered a very thrilling phase, encouraging us to accelerate further the development of our first-in-class, first-in-man cell-based gene therapies.”
Kosijer has 14 years’ experience in corporate finance and pharmaceutical contract service businesses including Accovion GmbH – a European clinical research organisation now owned by Clinipace – where he was CFO.
Christine Guenther, CEO of apceth, said: “With Dusan’s longstanding background as a finance executive in the pharmaceutical contract services sector, Dusan will play a major role in further strengthening our successful track record as one of the leading CDMOs for complex cell and gene therapy products.
“Moreover, Dusan’s experience will strongly promote our dynamic innovative strategy behind apceth’s unique proprietary pipeline of genetically modified stem cell therapies.”